A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

Chronic Hypoparathyroidism Clinical Trial

Official title:
A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism

Status Withdrawn

Clinical Trial Summary

This clinical study aims to evaluate the safety and efficacy of repeated dosing of recombinant human parathyroid hormone (rhPTH[1-84]) in Japanese participants with chronic hypoparathyroidism for a 26-week period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03878953
Study type	Interventional
Source	Takeda
Contact
Status	Withdrawn
Phase	Phase 3
Start date	August 31, 2022
Completion date	May 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05239221` - AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism	Phase 1/Phase 2
Completed	`NCT02910466` - A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism	Phase 4
Completed	`NCT03425747` - Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism	Phase 4
Active, not recruiting	`NCT05778071` - Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism	Phase 3
Completed	`NCT05214274` - Multicenter Registry Study of Chronic Hypoparathyroidism in Chinese Adults